share_log

NAYA Biosciences Announces Development Of NY-500 Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody

Benzinga ·  Jan 6 21:32

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications

• NAYA aiming to initiate clinical trials in early 2026

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment